ClinicalTrials.gg
CompletedNCT05446740Updated Mar 10, 2026Results posted

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

A Phase 1 interventional study of GSK4382276A Dose level 1 and GSK4382276A Dose level 2 in Influenza, Human, sponsored by GlaxoSmithKline. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.

Enrollment
83rd of 165
324 · median 324
Started
2022
with 1 other
Phase 1
22 of 187
1 open now
Registered
177th of 187
by date

Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 83rd largest by enrollment of the 165 interventional ones that give a count, is one of 2 that started in 2022, is one of 22 in phase 1, and was the 177th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Influenza, Human by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in healthy younger adults (YA) and older adults (OA).

03

Conditions studied

  • Influenza, Human

Browse trials for

Keywords

  • Influenza
  • Safety
  • Reactogenicity
  • Immunogenicity
  • mRNA vaccine
  • Healthy younger adults
  • Healthy older adults
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female between and including 18 and 45 years of age (YAs) or between and including 60 and 80 years of age (OAs) at the time of the study intervention administration. The age of sentinel participants in OA category will be limited to maximum 70 years.
  • Healthy or medically stable participants as established by medical history, safety laboratory assessments and clinical examination.
  • >= 18 kg/m\^2 and \<= 32 kg/m\^2.
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written obtained from the participant prior to performing any study-specific procedure.
  • Female participants of non- may be enrolled in the study.
  • Female participants of childbearing potential may be enrolled in the study if the participant:

    • has practiced adequate for 28 days prior to study intervention administration, and
    • has a negative pregnancy test on the day of study intervention administration, and
    • has agreed to continue adequate contraception for at least 1 month after study intervention administration.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Acute or chronic pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or review of the participant's medical record.
  • Any clinically significant hematological coagulation or urine analysis laboratory abnormality.

    * The investigator should use his/her clinical judgement to decide which abnormalities are clinically significant.

  • Current or past , unless completely resolved without sequelae for >5 years.
  • Any confirmed or suspected or immunodeficient condition, including infection, based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the study intervention (including latex, poly-ethylene-glycol, egg protein and aminoglycoside antibiotics).
  • Recurrent history or uncontrolled neurological disorders or seizures, including Guillain-Barré syndrome and Bell's palsy, with the exception of febrile seizures during childhood.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Significant exposure to persons with influenza or laboratory-confirmed SARS-CoV-2 within 7 days prior to Visit 1 (Day 1) and for whom a SARS-CoV-2 PCR test has not (yet) been confirmed as negative.

Prior/Concomitant therapy

  • Administration of seasonal influenza vaccine within 180 days before enrollment or planned administration up to Visit 4 (Day 29).
  • Administration of a vaccine not foreseen by the study protocol in the period starting 28 days before the study intervention administration, or planned administration within 28 days after the study intervention administration*, with the exception of vaccines authorized or approved for the prevention of COVID-19 (regardless of the type of vaccine).

    *In case emergency mass vaccination for an unforeseen public health threat is organized by public health authorities outside the routine immunization program, the time period described above can be reduced to 7 days, if necessary, for that mass vaccination vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.

  • Use of any or non-registered product (drug, vaccine or invasive medical device) other than the study intervention during the period beginning 30 days before the study intervention administration, or their planned use during the study period.
  • Administration of long-acting immune-modifying drugs within 90 days before enrollment or planned use at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration, or planned administration during the study period. Administration of monoclonal antibodies specifically directed against the spike protein of SARS-CoV-2 virus, for treatment of COVID-19 disease is allowed.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the study intervention administration. For , this will mean prednisone equivalent ≥ 20 mg/day. Inhaled, topical and intraarticular steroids are allowed.
  • Previous enrolment in this study.

Other exclusions

  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions within the 1-month post-dosing period.
  • History of abusive alcohol and/or drug consumption in the past 5 years.
  • Any study personnel or their immediate dependents, family, or household members.
  • Participants with extensive tattoos covering deltoid region on both arms that would preclude the assessment of local reactogenicity.
  • Previous enrollment in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    Flu mRNA_Dose level 1_Younger adults (YA)

    On Day 1, YA adult participants received Flu mRNA at Dose Level 1, the lowest concentration evaluated in the study.

    Biological: GSK4382276A Dose level 1

  • Experimental
    Flu mRNA_Dose level 2 _YA

    On Day 1, YA participants received Flu mRNA at Dose Level 2, which corresponds to a higher concentration than Dose Level 1.

    Biological: GSK4382276A Dose level 2

  • Experimental
    Flu mRNA_Dose level 3_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 3, which corresponds to a higher concentration than Dose Level 2.

    Biological: GSK4382276A Dose level 3

  • Experimental
    Flu mRNA_Dose level 4_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 4, which corresponds to a higher concentration than Dose Level 3.

    Biological: GSK4382276A Dose level 4

  • Experimental
    Flu mRNA_Dose level 5_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 5, which corresponds to a higher concentration than Dose Level 4.

    Biological: GSK4382276A Dose level 5

  • Experimental
    Flu mRNA_Dose level 6_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 6, which corresponds to a higher concentration than Dose Level 5.

    Biological: GSK4382276A Dose level 6

  • Experimental
    Flu mRNA_Dose level 7_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 7, which corresponds to a higher concentration than Dose Level 6.

    Biological: GSK4382276A Dose level 7

  • Experimental
    Flu mRNA_ Dose level 8_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 8, which corresponds to a higher concentration than Dose Level 7.

    Biological: GSK4382276A Dose level 8

  • Experimental
    Flu mRNA_Dose level 9_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 9, which corresponds to a higher concentration than Dose Level 8.

    Biological: GSK4382276A Dose level 9

  • Experimental
    Flu mRNA_Dose level 10_YA

    On Day 1, YA participants received Flu mRNA at Dose Level 10, the highest concentration evaluated in the study.

    Biological: GSK4382276A Dose level 10

  • Active comparator
    Pooled Control_YA

    On Day 1, YA participants received a single dose of FDQ21A - NH or FDQ22A -NH administered as a control and were analyzed together as pooled group throughout the study.

    Combination Product: FDQ21A-NH · Combination Product: FDQ22A-NH

  • Experimental
    Flu mRNA_Dose level 7_Older adults (OA)

    On Day 1, OA participants received Flu mRNA at Dose Level 7.

    Biological: GSK4382276A Dose level 7

  • Active comparator
    Control_OA

    On Day 1, OA participants received a single dose of FDQ21A-NH administered at as a control.

    Combination Product: FDQ21A-NH

Interventions

  • BiologicalGSK4382276A Dose level 1

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 2

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 3

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 4

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 5

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 6

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 7

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 8

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 9

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • BiologicalGSK4382276A Dose level 10

    Single dose of intervention administered at Day 1

    Also known as: Flu mRNA

  • Combination productFDQ21A-NH

    Single dose of intervention administered at Day 1

  • Combination productFDQ22A-NH

    Single dose of intervention administered at Day 1

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Any Solicited Administration Site Events

    Assessed solicited administration site events included pain, erythema/redness, swelling and Lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.

    Time frame: Day 1 to Day 7

  2. Number of Participants Reporting Any Solicited Systemic Events

    Assessed solicited systemic events included fever, chills, headache, myalgia, arthralgia and fatigue. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 to Day 7

  3. Number of Participants Reporting Any Unsolicited Adverse Events (AEs)

    An unsolicited AEs is an AEs that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs must have been communicated by a participant who has signed the informed consent or through his/her caregiver. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade or relation to study vaccination.

    Time frame: Day 1 to Day 28

  4. Number of Participants Reporting Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or resulted in abnormal pregnancy outcomes, or in other situations that were considered serious per medical or scientific judgment.

    Time frame: Day 1 to Day 183

  5. Number of Participants Reporting AEs of Special Interest (AESIs)

    The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs).

    Time frame: Day 1 to Day 183

  6. Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, Clinical Chemistry, Coagulation and Urine Analysis

    Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.

    Time frame: At Day 8 compared to baseline (Day 1)

  7. Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology,Clinical Chemistry, Coagulation and Urine Analysis

    Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.

    Time frame: At Day 29 compared to baseline (Day 1)

  8. Geometric Mean Titers (GMT) of Anti-vaccine Antibody Titers

    Time frame: At Day 1

  9. GMT of Anti-vaccine Antibody Titers

    Time frame: At Day 22

  10. Geometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 22

    GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titers over the Day 1 anti-vaccine antibody titers.

    Time frame: From Day 1 to Day 22

  11. Percentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR)

    SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer ≥ 1:40 or a pre-dose anti-vaccine antibody titer ≥ 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer.

    Time frame: From Day 1 to Day 22

  12. Percentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR)

    SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer ≥ 1:40.

    Time frame: At Day 22

Secondary outcomes

  1. GMT of Anti-vaccine Antibody Titers

    Time frame: At Day 62 and Day 183

  2. GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 62

    GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.

    Time frame: From Day 1 to Day 62

  3. GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 183

    GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.

    Time frame: From Day 1 to Day 183

  4. Percentage of Participants With Anti-vaccine Antibody SPR

    SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titers ≥ 1:40.

    Time frame: At Day 62 and Day 183

07

Results

Posted Mar 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Started24242424242424242524353216
Completed24242424242422242523353216
Not completed0000002001000
Withdrew: Lost to follow-up0000002001000

Outcome measures

PrimaryNumber of Participants Reporting Any Solicited Administration Site Events

Assessed solicited administration site events included pain, erythema/redness, swelling and Lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Erythema0000001236010
Pain5681416192121252425147
Swelling0001000256040
Lymphadenopathy01435479912900
PrimaryNumber of Participants Reporting Any Solicited Systemic Events

Assessed solicited systemic events included fever, chills, headache, myalgia, arthralgia and fatigue. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Arthralgia12333347615422
Chills100234941410120
Fatigue881291211161522221962
Headache11649791412191913124
Myalgia234545151320201351
Fever0010000228210
PrimaryNumber of Participants Reporting Any Unsolicited Adverse Events (AEs)

An unsolicited AEs is an AEs that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs must have been communicated by a participant who has signed the informed consent or through his/her caregiver. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade or relation to study vaccination.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)1313141713161216151324148
PrimaryNumber of Participants Reporting Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or resulted in abnormal pregnancy outcomes, or in other situations that were considered serious per medical or scientific judgment.

Time frame:
Day 1 to Day 183
Reported as:
Count of participants · Participants
Number of Participants Reporting Serious Adverse Events (SAEs)
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Number of Participants Reporting Serious Adverse Events (SAEs)1000200000110
PrimaryNumber of Participants Reporting AEs of Special Interest (AESIs)

The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs).

Time frame:
Day 1 to Day 183
Reported as:
Count of participants · Participants
Number of Participants Reporting AEs of Special Interest (AESIs)
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Number of Participants Reporting AEs of Special Interest (AESIs)0000000000000
PrimaryNumber of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, Clinical Chemistry, Coagulation and Urine Analysis

Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.

Time frame:
At Day 8 compared to baseline (Day 1)
Reported as:
Count of participants · Participants
Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, Clinical Chemistry, Coagulation and Urine Analysis
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Abnormal non-significant to clinically significant0000002000000
Normal or missing to clinically significant0200008000001
PrimaryNumber of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology,Clinical Chemistry, Coagulation and Urine Analysis

Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.

Time frame:
At Day 29 compared to baseline (Day 1)
Reported as:
Count of participants · Participants
Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology,Clinical Chemistry, Coagulation and Urine Analysis
ParticipantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Abnormal non-significant to clinically significant0000000100102
Normal or missing to clinically significant3002032000010
PrimaryGeometric Mean Titers (GMT) of Anti-vaccine Antibody Titers
Time frame:
At Day 1
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMT) of Anti-vaccine Antibody Titers
TitersFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Geometric Mean Titers (GMT) of Anti-vaccine Antibody Titers29.59 (16.05 to 54.56)53.97 (28.15 to 103.48)31.43 (17.67 to 55.91)28.67 (15.56 to 52.82)16.33 (9.58 to 27.84)16.33 (9.82 to 27.16)43.78 (22.19 to 86.38)21.23 (12.15 to 37.11)41.78 (22.90 to 76.26)54.14 (31.83 to 92.06)30.07 (17.46 to 51.78)38.65 (25.05 to 59.63)40.82 (19.90 to 83.75)
PrimaryGMT of Anti-vaccine Antibody Titers
Time frame:
At Day 22
Reported as:
Geometric mean · Titers
GMT of Anti-vaccine Antibody Titers
TitersFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
GMT of Anti-vaccine Antibody Titers269.00 (120.50 to 600.47)314.88 (139.83 to 709.07)420.90 (191.00 to 927.55)436.90 (198.46 to 961.79)509.49 (228.62 to 1135.46)574.09 (258.11 to 1276.91)1144.59 (520.12 to 2518.84)655.57 (308.11 to 1394.83)1124.85 (568.42 to 2226.00)923.79 (427.53 to 1996.07)313.07 (151.79 to 645.71)571.29 (384.74 to 848.30)245.66 (159.33 to 378.76)
PrimaryGeometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 22

GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titers over the Day 1 anti-vaccine antibody titers.

Time frame:
From Day 1 to Day 22
Reported as:
Geometric mean · Ratio
Geometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 22
RatioFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Geometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 228.62 (3.86 to 19.24)10.09 (4.48 to 22.72)13.49 (6.12 to 29.73)14.00 (6.36 to 30.82)16.33 (7.33 to 36.39)18.40 (8.27 to 40.92)36.68 (16.67 to 80.72)21.01 (9.87 to 44.70)36.05 (18.22 to 71.34)29.61 (13.70 to 63.97)10.03 (4.86 to 20.69)14.50 (9.76 to 21.53)6.23 (4.04 to 9.61)
PrimaryPercentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR)

SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer ≥ 1:40 or a pre-dose anti-vaccine antibody titer ≥ 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer.

Time frame:
From Day 1 to Day 22
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR)
Percentage of participantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Percentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR)47.8 (26.8 to 69.4)50.0 (28.2 to 71.8)82.6 (61.2 to 95.0)78.3 (56.3 to 92.5)95.7 (78.1 to 99.9)95.8 (78.9 to 99.9)87.0 (66.4 to 97.2)95.7 (78.1 to 99.9)95.8 (78.9 to 99.9)95.8 (78.9 to 99.9)59.4 (40.6 to 76.3)89.7 (72.6 to 97.8)56.3 (29.9 to 80.2)
PrimaryPercentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR)

SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer ≥ 1:40.

Time frame:
At Day 22
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR)
Percentage of participantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Percentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR)95.7 (78.1 to 99.9)100 (84.6 to 100)100 (85.2 to 100)100 (85.2 to 100)100 (85.2 to 100)100 (85.8 to 100)100 (85.2 to 100)100 (85.2 to 100)100 (85.8 to 100)100 (85.8 to 100)100 (89.1 to 100)96.6 (82.2 to 99.9)93.8 (69.8 to 99.8)
SecondaryGMT of Anti-vaccine Antibody Titers
Time frame:
At Day 62 and Day 183
Reported as:
Geometric mean · Titers
GMT of Anti-vaccine Antibody Titers
TitersFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Post-dosing at Day 62180.49 (81.00 to 402.16)165.29 (73.19 to 373.31)253.76 (116.06 to 554.84)325.51 (147.74 to 717.15)315.22 (143.52 to 692.32)315.45 (143.12 to 695.29)585.92 (254.77 to 1347.50)340.76 (162.66 to 713.89)703.32 (363.72 to 1360.01)—223.85 (106.67 to 469.74)304.72 (183.75 to 505.31)193.62 (108.73 to 344.78)
Post-dosing at Day 183139.93 (59.67 to 328.15)119.60 (50.66 to 282.35)183.46 (78.33 to 429.70)200.75 (86.89 to 463.83)173.18 (76.23 to 393.40)206.82 (91.11 to 469.51)202.41 (77.59 to 527.99)208.90 (95.63 to 456.32)307.75 (154.52 to 612.91)—192.15 (88.73 to 416.14)158.15 (82.85 to 301.90)122.32 (48.12 to 310.94)
SecondaryGMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 62

GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.

Time frame:
From Day 1 to Day 62
Reported as:
Geometric mean · Ratio
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 62
RatioFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 626.87 (3.08 to 15.32)6.29 (2.79 to 14.22)9.66 (4.42 to 21.13)12.40 (5.63 to 27.31)12.00 (5.47 to 26.36)12.01 (5.45 to 26.48)22.31 (9.70 to 51.31)12.98 (6.19 to 27.19)26.78 (13.85 to 51.79)—8.52 (4.06 to 17.89)8.05 (4.85 to 13.34)5.11 (2.87 to 9.10)
SecondaryGMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 183

GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.

Time frame:
From Day 1 to Day 183
Reported as:
Geometric mean · Ratio
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 183
RatioFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 1836.35 (2.71 to 14.90)5.43 (2.30 to 12.82)8.33 (3.56 to 19.51)9.12 (3.95 to 21.06)7.86 (3.46 to 17.87)9.39 (4.14 to 21.32)9.19 (3.52 to 23.98)9.49 (4.34 to 20.72)13.98 (7.02 to 27.83)—8.73 (4.03 to 18.90)3.73 (1.95 to 7.12)2.88 (1.13 to 7.33)
SecondaryPercentage of Participants With Anti-vaccine Antibody SPR

SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titers ≥ 1:40.

Time frame:
At Day 62 and Day 183
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-vaccine Antibody SPR
Percentage of participantsFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Post-dosing at Day 6295.2 (76.2 to 99.9)100 (82.4 to 100)100 (85.2 to 100)100 (83.9 to 100)95.8 (78.9 to 99.9)100 (85.8 to 100)100 (76.8 to 100)100 (80.5 to 100)100 (83.2 to 100)—100 (85.2 to 100)93.3 (68.1 to 99.8)90.0 (55.5 to 99.7)
Post-dosing at Day 18388.2 (63.6 to 98.5)94.1 (71.3 to 99.9)100 (79.4 to 100)100 (80.5 to 100)91.3 (72.0 to 98.9)91.7 (73.0 to 99.0)100 (63.1 to 100)100 (78.2 to 100)100 (83.2 to 100)—94.7 (74.0 to 99.9)83.3 (51.6 to 97.9)100 (54.1 to 100)

Adverse events

Collected over Solicited AEs: during the 7-day follow-up period after vaccination. Unsolicited AEs: during the 28-day follow-up period after vaccination. All-cause mortality, SAEs and AESIs: from first vaccination (Day 1) up to study end (Day 183). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flu mRNA_Dose Level 1_Younger Adults (YA)0/24 (0%)1/24 (4.2%)17/24 (70.8%)
Flu mRNA_Dose Level 2 _YA0/24 (0%)0/24 (0%)20/24 (83.3%)
Flu mRNA_Dose Level 3_YA0/24 (0%)0/24 (0%)21/24 (87.5%)
Flu mRNA_Dose Level 4_YA0/24 (0%)0/24 (0%)19/24 (79.2%)
Flu mRNA_Dose Level 5_YA0/24 (0%)2/24 (8.3%)22/24 (91.7%)
Flu mRNA_Dose Level 6_YA0/24 (0%)0/24 (0%)24/24 (100%)
Flu mRNA_Dose Level 7_YA0/24 (0%)0/24 (0%)23/24 (95.8%)
Flu mRNA_ Dose Level 8_YA0/24 (0%)0/24 (0%)23/24 (95.8%)
Flu mRNA_Dose Level 9_YA0/25 (0%)0/25 (0%)25/25 (100%)
Flu mRNA_Dose Level 10_YA0/24 (0%)0/24 (0%)24/24 (100%)
Pooled Control_YA0/35 (0%)1/35 (2.9%)32/35 (91.4%)
Flu mRNA_Dose Level 7_Older Adults (OA)0/32 (0%)1/32 (3.1%)24/32 (75%)
Control_OA0/16 (0%)0/16 (0%)12/16 (75%)
Most frequent serious events
Most frequent serious events
EventFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Craniofacial fractureInjury, poisoning and procedural complications1/240/240/240/240/240/240/240/240/250/240/350/320/16
Poisoning deliberateInjury, poisoning and procedural complications0/240/240/240/241/240/240/240/240/250/240/350/320/16
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/240/240/240/241/240/240/240/240/250/240/350/320/16
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/240/240/240/241/240/240/240/240/250/240/350/320/16
Abdominal infectionInfections and infestations0/240/240/240/240/240/240/240/240/250/240/351/320/16
DepressionPsychiatric disorders0/240/240/240/240/240/240/240/240/250/241/350/320/16
Most frequent other events
Showing 10 of 118
Most frequent other events
EventFlu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OA
Administration site painGeneral disorders5/246/248/2414/2416/2419/2421/2421/2425/2524/2425/3514/327/16
FatigueGeneral disorders8/248/2412/2410/2412/2411/2416/2415/2422/2522/2420/357/322/16
MyalgiaMusculoskeletal and connective tissue disorders3/243/244/245/245/246/2415/2413/2420/2520/2413/357/321/16
HeadacheNervous system disorders11/248/248/2410/249/2411/2414/2413/2419/2519/2417/3512/325/16
ArthralgiaMusculoskeletal and connective tissue disorders2/242/243/243/243/244/244/248/246/2515/244/354/323/16
ChillsGeneral disorders1/240/240/242/243/244/249/244/2414/2510/241/353/320/16
LymphadenopathyBlood and lymphatic system disorders0/241/244/243/245/244/247/249/249/2512/2410/350/320/16
PyrexiaGeneral disorders0/240/241/240/240/240/240/242/242/258/242/351/320/16
Administration site erythemaGeneral disorders0/240/240/240/240/240/241/242/243/256/240/351/320/16
Administration site swellingGeneral disorders0/240/240/241/240/240/240/242/245/256/240/354/320/16

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Flu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OATotal
YA30.2 ± 8.532.5 ± 7.634.6 ± 7.335.7 ± 7.830.5 ± 9.530.7 ± 8.129.8 ± 7.635.8 ± 7.127.8 ± 5.729.1 ± 5.832.0 ± 7.8——31.7 ± 7.9
OA———————————66.8 ± 4.167.9 ± 4.667.2 ± 4.3
Sex: Female, Male
Sex: Female, Male(Participants)Flu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OATotal
Female1716111515111514201122205192
Male78139913910513131211132
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Flu mRNA_Dose Level 1_Younger Adults (YA)Flu mRNA_Dose Level 2 _YAFlu mRNA_Dose Level 3_YAFlu mRNA_Dose Level 4_YAFlu mRNA_Dose Level 5_YAFlu mRNA_Dose Level 6_YAFlu mRNA_Dose Level 7_YAFlu mRNA_ Dose Level 8_YAFlu mRNA_Dose Level 9_YAFlu mRNA_Dose Level 10_YAPooled Control_YAFlu mRNA_Dose Level 7_Older Adults (OA)Control_OATotal
Asian00100200000003
Black or African American00000000100001
American Indian or Alaska Native00000000300014
White24242324242224242124353215316
08

Study locations

7 sites
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Halifax, Nova Scotia B3J 3G9, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1L 0H8, Canada
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Madrid, 28222, Spain
09

References and documents

Publications

  • Leroux-Roels I, De Coster I, Borobia AM, Langley JM, Ochoa Mazarro D, Ruiz-Antoran B, Berre S, Germain S, Knauer C, Koch SD, Mann P, Mesia Vela D, Ovbude LJ, Pardo IA, Srivastava B, Moldt B, Nordgren M. Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study. Hum Vaccin Immunother. 2026 Dec;22(1):2631804. doi: 10.1080/21645515.2026.2631804. Epub 2026 Feb 17. PubMed 41701031 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2024, 19 months.

Results were first posted in Mar 2026, 1 year 11 months after primary completion.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 19 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 7, 2022
StartActual
Aug 9, 2022
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Results first posted
Mar 10, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05446740
Lead sponsor
GlaxoSmithKline
Collaborators
CureVac
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Aug 9, 2022
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Results posted
Mar 10, 2026
Last update
Mar 10, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion